器官移植临床经验以及并发肺癌患者的生存分析
|
摘要
背景
自从1906年Mathieu报道首例肾移植开始，人类对器官移植的探索从未停止过，随着外科技术的日臻完善以及新型免疫抑制剂的不断更新，器官移植在临床已经作为部分器官功能衰竭的替代性治疗手段。同时，因为所涉及医学理论同外科技巧的复杂性与难度，器官移植又被称为21世纪医学领域的珠穆朗玛峰。目前，临床移植对器官移植的关注焦点不仅限于排斥反应的控制，还注重患者以及危重患者的长期生存质量，如：对多器官联合移植的研究、移植相关肿瘤发生的分析、ABO血型不相符的器官移植，移植术后心血管并发症的防治、移植受者妊娠等等。本文对多器官联合移植(以肝肾联合移植为例)以及移植相关肿瘤(以并发肺癌为例)的研究分述如下：
第一部分肝肾联合移植的临床经验
第一章肝肾联合移植的临床经验
第二章肝肾联合移植中肝脏对肾脏的保护作用
第二部分器官移植并发肺癌患者的生存分析
第一章器官移植后肺癌患者的生存分析
第二章肺癌患者器官移植后的生存分析
第一部分肝肾联合移植的临床经验
第一章肝肾联合移植的临床经验
目的：探讨肝肾联合移植的适应证，手术技术，治疗经验以及并发症的防治。
方法：2001年10月至2006年6月进行肝肾联合移植18例。男13例，女5例。年龄41-71岁，平均57.9岁。原发病：多囊肝、多囊肾并尿毒症8例，酒精性肝硬化合并尿毒症2例，乙型肝炎肝硬化合并尿毒症7例，肾移植术后14年丙型肝炎肝硬化导致肝衰伴移植肾功能不全尿毒症1例。肝移植采用经典非转流原位肝移植术式和背驮式肝移植术式，肾移植为常规术式。病肝切除时注意细致分离第三肝门、创面及时止血。以抗胸腺淋巴细胞免疫球蛋白或白介素-2受体单克隆抗体作为免疫诱导，术后服用他克莫司、霉酚酸酯以及激素维持免疫抑制治疗。患者门诊随访，复查血、尿常规，肝肾功能，他克莫司血药浓度以及移植物B超等项目。随访时间2个月～4年10个月。
结果：18例手术均取得成功。16例存活至今，肝肾功能正常，其中存活4年10个月者1例，存活3年以上者2例，2年以上者6例，1年以上者4例，1年以内3例。1例49岁患者术后1年6个月死于心肌梗塞，1例52岁患者术后1年1个月死于肺部巨细胞病毒(CMV)感染。术后发生急性排斥反应1例，继发性出血1例，心肌梗塞1例(死亡)，胸腔积液4例，肺部感染3例(1例死亡)。除死亡病例外，所有并发症经相应治疗后逆转治愈。
结论：肝肾联合移植是肝肾功能衰竭的有效治疗手段。娴熟的手术技巧、围手术期细心管理、并发症的及时诊治是肝肾联合移植成功的关键。
第二章肝肾联合移植中肝脏对肾脏的保护作用
目的：探讨肝肾联合移植中肝脏对肾脏的保护作用。
方法：回顾分析2001年10月至2006年6月接受肝肾联合移植的18例患者，并以同一供体的对侧肾脏所完成的单独肾移植18例受者作为对照，2组间患者年龄、性别、血型、冷热缺血时间、人类白细胞抗原(HLA)配型、肾病原发病、免疫抑制方案等条件基本相匹配。对2组间移植肾急性排斥反应(AR)、慢性排斥反应(CR)、移植肾功能延迟恢复(DGF)的发生率以及出院时患者血清肌酐(Cr)改善水平进行比较。
结果：肝肾联合移植组AR和DGF发生率明显均低于单独肾移植组，统计学差异显著(5.56％vs 33.3％P=0.035；0 vs 27.8％P=0.045)；肝肾联合移植组CR发生率明显低于单独肾移植组，但统计学差异不明显(0 vs 11.1％P=0.486)。出院时平均Cr水平肝肾联合移植组明显优于单独肾移植组，统计学差异显著(77.6±23.4umol／L vs 123.1±23.8umol／L P=0.000)。
结论：肝肾联合移植中肝脏对肾脏具有保护作用，能够维持良好的移植肾功能。
第二部分器官移植并发肺癌患者的生存分析
肺癌在普通人群中为第二位高发肿瘤，并且已经成为全球因肿瘤导致死亡的最主要原因。在美国，无论在男性还是女性，肺癌都已列为头号肿瘤杀手，其导致的死亡率为70／100000。在欧盟，肿瘤致死的病因中，1／3为肺癌。在中国，男性中因肺癌导致的死亡率为33／100000，并且在今后的几十年还会继续上升。器官移植的受者中，恶性肿瘤已经成为非常重要的并发症，发病率为平均每年1-2％，其中皮肤癌、淋巴瘤、肾癌等，发病率高达5-10％，并且随着移植后免疫抑制时间的延长，发病风险每年增加1-2％。在器官移植受者中新发肺癌以及肺癌后接受器官移植的患者生存情况并不清楚，文献报道仅限于单中心的小样本调查。本文以Israel Penn国际移植肿瘤登记处(Israel Penn International Transplant Tumor Registry，IPITTR)录入的器官移植术后新发肺癌患者(662例)以及肺癌后接受器官移植的患者(28例)的临床资料，对影响患者生存率的因素进行分析。
第一章：器官移植后肺癌患者的生存分析
目的：了解器官移植后新发肺癌患者影响其生存率的各类因素。
方法：对1968年11月至2006年12月向Israel Penn International Transplant Tumor Registry报告的器官移植后新发肺癌病例的存活时间进行多因素分析。
采用SPSS 11.5统计软件。以Cox回归模型分析多种因素对生存时间的影响，Kaplan-Meier法比较肿瘤分期对生存时间的影响。P值小于0.05认为具有统计学差异。
结果：662例患者于器官移植后平均第44个月(0-1054)时诊断肺癌。总体存活率为33％。患者移植时年龄偏大(P=0.033)，病理诊断为小细胞肺癌(P=0004)以及接受ATG／ALG／OKT_3抗体诱导治疗(P=0.032)的患者死亡风险升高，并具有统计学意义。外科手术切除肿瘤病灶(P=0.000)、化疗(P=0.001)可以改善患者的生存率，并具有统计学意义。依据病理分期，四期肿瘤患者生存时间具有统计学差异(P=0.000)。患者性别、种族、诊断时年龄、移植-诊断时间、供器官类型、移植器官种类、以及除抗体类以外的免疫抑制剂类型同患者的生存时间无统计学相关性。
结论：
1．免疫抑制使得肺癌进展迅速，预后差。
2．移植时年龄较大、病理类型为小细胞肺癌、经ATG／ALG／OKT_3抗体诱导治疗、以及晚期肿瘤使得患者死亡风险升高；
3．外科切除、化疗可以改善患者生存率；
4．以常规方法治疗肿瘤的同时减少免疫抑制剂用量。停用抗代谢药物，通常根据患者血药浓度减少25-50％CNI剂量；
5．器官移植后对于有吸烟史的高危患者群应密切注意肺部的随访；
6．我国可借鉴IPITTR模式建立相应的移植登记处，以便资料汇总、分析，有助于移植受者的治疗及随访。
第二章：肺癌患者器官移植后的生存分析
目的：了解肺癌患者器官移植后的生存情况。
方法：对1968年11月至2006年12月向Israel Penn International Transplant Tumor Registry报告的肺癌患者接受器官移植后存活时间进行多因素分析。采用SPSS 11.5统计软件。以Cox回归模型分析多种因素对生存时间的影响。P值小于0.05认为具有统计学差异。
结果：1968年11月至2006年12月期间，IPITTR共有28例移植前既发肺癌患者，因病理分期资料不完全，其对生存时间的影响未纳入分析。患者性别、种族、诊断以及移植时年龄、诊断-移植时间、供器官类型、移植器官种类、免疫抑制剂类型以及肿瘤复发同患者的生存时间均无统计学相关性。移植术后出现6例肺癌复发(21％)，均在术后5年内复发。死亡9例，均在移植后5年内死亡，总体生存率为68％，死亡率为32％。
结论：
1．结合文献，仅早期肺癌患者肿瘤切除后可作为器官移植受者，且移植后存活率并不理想。
2．普通人群中肺癌患者的生存曲线于诊断后5年开始趋于平缓，因此建议肺癌患者接受器官移植的等待时间为至少5年。
Explores in organ transplantation have been continuing since the first kidneytransplantation in human was reported in 1906. With the development of surgicaltechnique and immunosuppression agents, organ transplantation has been the highestand hardest field in medical science. Current clinic focuses of transplantation are onlong-term outcome and intense recipients as well as acute and chronic rejection, suchas multiple organ transplantation, transplant-related malignance, cardiovasculardisease post transplantation and pregnancy in recipients. This article will provide theresearch on combined liver-kidney transplantation and analysis of multivariatefactors that influence survival with lung cancer in recipients as follows:
PartⅠExperience with combined liver-kidney transplantation
ChapterⅠExperience with combined liver-kidney transplantation
ChapterⅡA liver graft from the same donor protect a kidney in combinedliver-kidney transplantation
PartⅡAnalysis of multivariate factors that influence survival with lungcancer in recipients
ChapterⅠMultivariate risk factors survival analysis of de novo lung cancerin organ transplant recipients
ChapterⅡMultivariate risk factors survival analysis of pre-existing lungcancer in organ transplant recipients
PartⅠExperience with combined liver-kidney transplantation
ChapterⅠExperience with combined liver-kidney transplantation
Objective To describe the indications, surgical techniques, clinical experiences andtreatment of complications of combined liver-kidney transplantation (CLKT).Methods 18 cases subject to CLKT from Oct 2001 to June 2006 were reviewed inour center. 13 men and 5 women. Median age 57.9ys, age range 41 to 71ys. Primarydiseases as follow: 8 polycystic liver and kidney with uremia, 2 alcoholic cirrhosiswith uremia, 7 liver cirrhosis led by Hepatitis B with uremia, 1 liver cirrhosis led byHepatitis C and grafted renal failure 14 years after transplantation. Livertransplantations were performed with piggyback style or standard techniques withoutveno-venous bypass. Kidney transplantation followed routines. Care should be takenon third hepatic portal during hepatectomy. Immunosuppressive therapy includedATG or basilimab as introduction and Tacrolimus/Mycophenolate mofetil/steroid.The period of follow up ranges from 2 months to 4 years and 10 months.
Results All the 18 operations were completed successfully. 16 are alive till nowwith good liver and kidney function. Among the 16 cases, the longest survival time is4 years and 10 months, 2 patients' are over 3 years, 6 are over 2 years, 3 are over 1year and 3 are within 1 year. ldied of myocardial infarction on the eighteenth monthafter Tx. The other died of cytomegalovirus (CMV) infection of lung on thirteenthmonth. Complications included 1 acute rejection, 1 secondary hemorrhage, 1myocardial infarction, hydrothorax in 4, and pulmonary infection in 3. Except for 2dead cases, other compilations were rescued after therapy.
Conclusions CLKT is an effective treatment method for liver and renal function failure. Proficient surgical skill and immediate management of complications arecrucial for successful CLKT.
ChapterⅡA liver graft from the same donor protect a kidney in combinedliver-kidney transplantation
Objective To compare the improvement of renal graft function of combined liver-kidney transplantation(CLKT) and kidney alone transplantation(KAT).
Methods The data of 18 CLKT and 18 contralateral kidney alone transplantationswere analyzed. The two groups Were matched in the following variables: age, gender,blood type, cold and warm ischemic time of the grafts, human leukocyte antigen(HLA), primary renal disease, and use of immunosuppressants. Incidences of acuterejection, chronic rejection, delayed graft function and improved serum creatinine (Cr)on discharge were compared.
Results The rates of acute rejection and delayed graft function were much lower inCLKT than that in KAT with significant difference (5.56% vs 33.3% P=0.035; 0vs 27.8% P=0.045). CR incidence was lower in CLKT without significantdifference (0 vs 11.1% P=0.486) . There was much lower Cr lever in CLKT thanthat in KAT (77.6±23.4umol/L vs 123.1±23.8umol/L P=0.000).
Conclusions Analysis of the data indicates an allograft enhancing perfect effect ofliver transplantation on the renal allograft in combined liver- kidney transplantation.
PartⅡAnalysis of multivariate factors that influence survivalwith lung cancer in recipients
Lung cancer ranks among the most commonly occurring malignancies and currentlyis the leading cause of cancer-related deaths worldwide. In the United States, lungcancer is the most common cause of cancer-related deaths in men as well in women,with an incidence approximating 70 per 100,000 in individuals. Lung cancercurrently accounts for one-third of all cancer-related deaths in the European Union.In China, the mortality rate from lung cancer in males now approximates 33 per100,000, and death rates are expected to substantially increase over the next severaldecades. Transplant recipients develop malignancies at a rate of 1-2%approximately per year but this is higher (5-10%) for certain types of cancer (skin,lymphoma, kidney) and the overall rate of 1-2% increases in subsequent years withlonger exposure times to immunosuppressive drugs. However, the effects of organtransplantation on lung cancer incidence in recipients are unclear, literatures onwhich are limited to single center and small samples. Multivariate risk factorssurvival analysis of organ transplantation recipients with de novo (n=662) andpre-existing (n=28) lung cancer reported to the Israel Penn International TransplantTumor Registry from November 1968 to December 2006 was performed.
ChapterⅠMultivariate risk factors survival analysis of de novo lung cancer inorgan transplant recipients
Objective To investigate the risk factors that influence survival of de novo lungcancer in organ transplant recipients
Methods Multivariate risk factors survival analysis of lung cancer post organtransplantation reported to the Israel Penn International Transplant Tumor Registryfrom November 1968 to December 2006 was performed.
Results Lung cancer presented 44 months (median) (range 0-1054) in 662 patientspost organ transplantation. Overall survival was 33%. Death risks were increased forthose who were older (P=0.033) at transplant, diagnosed with small cell lung cancer(P=0.004), and administered with ATG/ALG/OKT_3 (P=0.032) for induction therapy.Surgery (P=0.000) and chemotherapy (P=0.001) were associated with increasedsurvival. Stage makes difference in survival time in recipients (P=0.000). Nodifferences in death risk for age at diagnoses, gender, race, time from transplantationto diagnosis, donor type, transplantation organ and other immunosuppression wereidentified.
Conclusion
1. Lung cancer takes rapid progress and grim outcome under immunosuppression.
2. Death risk was increased for patients with older age at transplantation, histology ofsmall cell lung cancer, induction therapy with ATG/ALG/OKT_3 and later stage oftumor.
3. Death risk was improved for those receiving surgery and chemotherapy.
4. We would suggest immunosuppression regulation with discontinuation of antimetabolites, and 25-50％reduction in CNI dose.
5. Close surveillance is needed for the recipients that used to be heavy smokers.
6. Similar registry as IPITTR should be set up in China transplant community forbetter outcome and follow up for the transplant recipients.
ChapterⅡMultivariate risk factors survival analysis of pre-existing lungcancer in organ transplant recipients
Objective To investigate the risk factors that influence survival of pre-existing lungcancer in organ transplant recipients
Methods Multivariate risk factors survival analysis of pre-existing lung cancer inorgan transplant recipients reported to the Israel Penn International Transplant TumorRegistry from November 1968 to December 2006 was performed.
Results The IPITTR has reviewed a series of 28 cases of pre-existing lung cancer intransplant recipients. Stage data were not included for analysis because of incompleterecords. No differences in death risk for age at diagnoses or transplantation, gender,race, wait time from diagnosis to transplantation, donor type, transplantation organand immunosuppression agents were identified. Recurrences in 6 (21％) patientsoccurred within 5 years post transplantation. 9 patients died within 5 years. Overallsurvival was 68％and mortality was 32％.
Conclusion
1. In literature, transplantation is generally acceptable for only patients with earlystage disease. Overall survival rate has not been good.
2. Survival cures of lung cancer do not begin to flatten until 5 years post diagnosis ingeneral populations. We would recommend 5 years of disease free prior totransplantation.
自从1906年Mathieu报道首例肾移植开始，人类对器官移植的探索从未停止过，随着外科技术的日臻完善以及新型免疫抑制剂的不断更新，器官移植在临床已经作为部分器官功能衰竭的替代性治疗手段。同时，因为所涉及医学理论同外科技巧的复杂性与难度，器官移植又被称为21世纪医学领域的珠穆朗玛峰。目前，临床移植对器官移植的关注焦点不仅限于排斥反应的控制，还注重患者以及危重患者的长期生存质量，如：对多器官联合移植的研究、移植相关肿瘤发生的分析、ABO血型不相符的器官移植，移植术后心血管并发症的防治、移植受者妊娠等等。本文对多器官联合移植(以肝肾联合移植为例)以及移植相关肿瘤(以并发肺癌为例)的研究分述如下：
第一部分肝肾联合移植的临床经验
第一章肝肾联合移植的临床经验
第二章肝肾联合移植中肝脏对肾脏的保护作用
第二部分器官移植并发肺癌患者的生存分析
第一章器官移植后肺癌患者的生存分析
第二章肺癌患者器官移植后的生存分析
第一部分肝肾联合移植的临床经验
第一章肝肾联合移植的临床经验
目的：探讨肝肾联合移植的适应证，手术技术，治疗经验以及并发症的防治。
方法：2001年10月至2006年6月进行肝肾联合移植18例。男13例，女5例。年龄41-71岁，平均57.9岁。原发病：多囊肝、多囊肾并尿毒症8例，酒精性肝硬化合并尿毒症2例，乙型肝炎肝硬化合并尿毒症7例，肾移植术后14年丙型肝炎肝硬化导致肝衰伴移植肾功能不全尿毒症1例。肝移植采用经典非转流原位肝移植术式和背驮式肝移植术式，肾移植为常规术式。病肝切除时注意细致分离第三肝门、创面及时止血。以抗胸腺淋巴细胞免疫球蛋白或白介素-2受体单克隆抗体作为免疫诱导，术后服用他克莫司、霉酚酸酯以及激素维持免疫抑制治疗。患者门诊随访，复查血、尿常规，肝肾功能，他克莫司血药浓度以及移植物B超等项目。随访时间2个月～4年10个月。
结果：18例手术均取得成功。16例存活至今，肝肾功能正常，其中存活4年10个月者1例，存活3年以上者2例，2年以上者6例，1年以上者4例，1年以内3例。1例49岁患者术后1年6个月死于心肌梗塞，1例52岁患者术后1年1个月死于肺部巨细胞病毒(CMV)感染。术后发生急性排斥反应1例，继发性出血1例，心肌梗塞1例(死亡)，胸腔积液4例，肺部感染3例(1例死亡)。除死亡病例外，所有并发症经相应治疗后逆转治愈。
结论：肝肾联合移植是肝肾功能衰竭的有效治疗手段。娴熟的手术技巧、围手术期细心管理、并发症的及时诊治是肝肾联合移植成功的关键。
第二章肝肾联合移植中肝脏对肾脏的保护作用
目的：探讨肝肾联合移植中肝脏对肾脏的保护作用。
方法：回顾分析2001年10月至2006年6月接受肝肾联合移植的18例患者，并以同一供体的对侧肾脏所完成的单独肾移植18例受者作为对照，2组间患者年龄、性别、血型、冷热缺血时间、人类白细胞抗原(HLA)配型、肾病原发病、免疫抑制方案等条件基本相匹配。对2组间移植肾急性排斥反应(AR)、慢性排斥反应(CR)、移植肾功能延迟恢复(DGF)的发生率以及出院时患者血清肌酐(Cr)改善水平进行比较。
结果：肝肾联合移植组AR和DGF发生率明显均低于单独肾移植组，统计学差异显著(5.56％vs 33.3％P=0.035；0 vs 27.8％P=0.045)；肝肾联合移植组CR发生率明显低于单独肾移植组，但统计学差异不明显(0 vs 11.1％P=0.486)。出院时平均Cr水平肝肾联合移植组明显优于单独肾移植组，统计学差异显著(77.6±23.4umol／L vs 123.1±23.8umol／L P=0.000)。
结论：肝肾联合移植中肝脏对肾脏具有保护作用，能够维持良好的移植肾功能。
第二部分器官移植并发肺癌患者的生存分析
肺癌在普通人群中为第二位高发肿瘤，并且已经成为全球因肿瘤导致死亡的最主要原因。在美国，无论在男性还是女性，肺癌都已列为头号肿瘤杀手，其导致的死亡率为70／100000。在欧盟，肿瘤致死的病因中，1／3为肺癌。在中国，男性中因肺癌导致的死亡率为33／100000，并且在今后的几十年还会继续上升。器官移植的受者中，恶性肿瘤已经成为非常重要的并发症，发病率为平均每年1-2％，其中皮肤癌、淋巴瘤、肾癌等，发病率高达5-10％，并且随着移植后免疫抑制时间的延长，发病风险每年增加1-2％。在器官移植受者中新发肺癌以及肺癌后接受器官移植的患者生存情况并不清楚，文献报道仅限于单中心的小样本调查。本文以Israel Penn国际移植肿瘤登记处(Israel Penn International Transplant Tumor Registry，IPITTR)录入的器官移植术后新发肺癌患者(662例)以及肺癌后接受器官移植的患者(28例)的临床资料，对影响患者生存率的因素进行分析。
第一章：器官移植后肺癌患者的生存分析
目的：了解器官移植后新发肺癌患者影响其生存率的各类因素。
方法：对1968年11月至2006年12月向Israel Penn International Transplant Tumor Registry报告的器官移植后新发肺癌病例的存活时间进行多因素分析。
采用SPSS 11.5统计软件。以Cox回归模型分析多种因素对生存时间的影响，Kaplan-Meier法比较肿瘤分期对生存时间的影响。P值小于0.05认为具有统计学差异。
结果：662例患者于器官移植后平均第44个月(0-1054)时诊断肺癌。总体存活率为33％。患者移植时年龄偏大(P=0.033)，病理诊断为小细胞肺癌(P=0004)以及接受ATG／ALG／OKT_3抗体诱导治疗(P=0.032)的患者死亡风险升高，并具有统计学意义。外科手术切除肿瘤病灶(P=0.000)、化疗(P=0.001)可以改善患者的生存率，并具有统计学意义。依据病理分期，四期肿瘤患者生存时间具有统计学差异(P=0.000)。患者性别、种族、诊断时年龄、移植-诊断时间、供器官类型、移植器官种类、以及除抗体类以外的免疫抑制剂类型同患者的生存时间无统计学相关性。
结论：
1．免疫抑制使得肺癌进展迅速，预后差。
2．移植时年龄较大、病理类型为小细胞肺癌、经ATG／ALG／OKT_3抗体诱导治疗、以及晚期肿瘤使得患者死亡风险升高；
3．外科切除、化疗可以改善患者生存率；
4．以常规方法治疗肿瘤的同时减少免疫抑制剂用量。停用抗代谢药物，通常根据患者血药浓度减少25-50％CNI剂量；
5．器官移植后对于有吸烟史的高危患者群应密切注意肺部的随访；
6．我国可借鉴IPITTR模式建立相应的移植登记处，以便资料汇总、分析，有助于移植受者的治疗及随访。
第二章：肺癌患者器官移植后的生存分析
目的：了解肺癌患者器官移植后的生存情况。
方法：对1968年11月至2006年12月向Israel Penn International Transplant Tumor Registry报告的肺癌患者接受器官移植后存活时间进行多因素分析。采用SPSS 11.5统计软件。以Cox回归模型分析多种因素对生存时间的影响。P值小于0.05认为具有统计学差异。
结果：1968年11月至2006年12月期间，IPITTR共有28例移植前既发肺癌患者，因病理分期资料不完全，其对生存时间的影响未纳入分析。患者性别、种族、诊断以及移植时年龄、诊断-移植时间、供器官类型、移植器官种类、免疫抑制剂类型以及肿瘤复发同患者的生存时间均无统计学相关性。移植术后出现6例肺癌复发(21％)，均在术后5年内复发。死亡9例，均在移植后5年内死亡，总体生存率为68％，死亡率为32％。
结论：
1．结合文献，仅早期肺癌患者肿瘤切除后可作为器官移植受者，且移植后存活率并不理想。
2．普通人群中肺癌患者的生存曲线于诊断后5年开始趋于平缓，因此建议肺癌患者接受器官移植的等待时间为至少5年。
Explores in organ transplantation have been continuing since the first kidneytransplantation in human was reported in 1906. With the development of surgicaltechnique and immunosuppression agents, organ transplantation has been the highestand hardest field in medical science. Current clinic focuses of transplantation are onlong-term outcome and intense recipients as well as acute and chronic rejection, suchas multiple organ transplantation, transplant-related malignance, cardiovasculardisease post transplantation and pregnancy in recipients. This article will provide theresearch on combined liver-kidney transplantation and analysis of multivariatefactors that influence survival with lung cancer in recipients as follows:
PartⅠExperience with combined liver-kidney transplantation
ChapterⅠExperience with combined liver-kidney transplantation
ChapterⅡA liver graft from the same donor protect a kidney in combinedliver-kidney transplantation
PartⅡAnalysis of multivariate factors that influence survival with lungcancer in recipients
ChapterⅠMultivariate risk factors survival analysis of de novo lung cancerin organ transplant recipients
ChapterⅡMultivariate risk factors survival analysis of pre-existing lungcancer in organ transplant recipients
PartⅠExperience with combined liver-kidney transplantation
ChapterⅠExperience with combined liver-kidney transplantation
Objective To describe the indications, surgical techniques, clinical experiences andtreatment of complications of combined liver-kidney transplantation (CLKT).Methods 18 cases subject to CLKT from Oct 2001 to June 2006 were reviewed inour center. 13 men and 5 women. Median age 57.9ys, age range 41 to 71ys. Primarydiseases as follow: 8 polycystic liver and kidney with uremia, 2 alcoholic cirrhosiswith uremia, 7 liver cirrhosis led by Hepatitis B with uremia, 1 liver cirrhosis led byHepatitis C and grafted renal failure 14 years after transplantation. Livertransplantations were performed with piggyback style or standard techniques withoutveno-venous bypass. Kidney transplantation followed routines. Care should be takenon third hepatic portal during hepatectomy. Immunosuppressive therapy includedATG or basilimab as introduction and Tacrolimus/Mycophenolate mofetil/steroid.The period of follow up ranges from 2 months to 4 years and 10 months.
Results All the 18 operations were completed successfully. 16 are alive till nowwith good liver and kidney function. Among the 16 cases, the longest survival time is4 years and 10 months, 2 patients' are over 3 years, 6 are over 2 years, 3 are over 1year and 3 are within 1 year. ldied of myocardial infarction on the eighteenth monthafter Tx. The other died of cytomegalovirus (CMV) infection of lung on thirteenthmonth. Complications included 1 acute rejection, 1 secondary hemorrhage, 1myocardial infarction, hydrothorax in 4, and pulmonary infection in 3. Except for 2dead cases, other compilations were rescued after therapy.
Conclusions CLKT is an effective treatment method for liver and renal function failure. Proficient surgical skill and immediate management of complications arecrucial for successful CLKT.
ChapterⅡA liver graft from the same donor protect a kidney in combinedliver-kidney transplantation
Objective To compare the improvement of renal graft function of combined liver-kidney transplantation(CLKT) and kidney alone transplantation(KAT).
Methods The data of 18 CLKT and 18 contralateral kidney alone transplantationswere analyzed. The two groups Were matched in the following variables: age, gender,blood type, cold and warm ischemic time of the grafts, human leukocyte antigen(HLA), primary renal disease, and use of immunosuppressants. Incidences of acuterejection, chronic rejection, delayed graft function and improved serum creatinine (Cr)on discharge were compared.
Results The rates of acute rejection and delayed graft function were much lower inCLKT than that in KAT with significant difference (5.56% vs 33.3% P=0.035; 0vs 27.8% P=0.045). CR incidence was lower in CLKT without significantdifference (0 vs 11.1% P=0.486) . There was much lower Cr lever in CLKT thanthat in KAT (77.6±23.4umol/L vs 123.1±23.8umol/L P=0.000).
Conclusions Analysis of the data indicates an allograft enhancing perfect effect ofliver transplantation on the renal allograft in combined liver- kidney transplantation.
PartⅡAnalysis of multivariate factors that influence survivalwith lung cancer in recipients
Lung cancer ranks among the most commonly occurring malignancies and currentlyis the leading cause of cancer-related deaths worldwide. In the United States, lungcancer is the most common cause of cancer-related deaths in men as well in women,with an incidence approximating 70 per 100,000 in individuals. Lung cancercurrently accounts for one-third of all cancer-related deaths in the European Union.In China, the mortality rate from lung cancer in males now approximates 33 per100,000, and death rates are expected to substantially increase over the next severaldecades. Transplant recipients develop malignancies at a rate of 1-2%approximately per year but this is higher (5-10%) for certain types of cancer (skin,lymphoma, kidney) and the overall rate of 1-2% increases in subsequent years withlonger exposure times to immunosuppressive drugs. However, the effects of organtransplantation on lung cancer incidence in recipients are unclear, literatures onwhich are limited to single center and small samples. Multivariate risk factorssurvival analysis of organ transplantation recipients with de novo (n=662) andpre-existing (n=28) lung cancer reported to the Israel Penn International TransplantTumor Registry from November 1968 to December 2006 was performed.
ChapterⅠMultivariate risk factors survival analysis of de novo lung cancer inorgan transplant recipients
Objective To investigate the risk factors that influence survival of de novo lungcancer in organ transplant recipients
Methods Multivariate risk factors survival analysis of lung cancer post organtransplantation reported to the Israel Penn International Transplant Tumor Registryfrom November 1968 to December 2006 was performed.
Results Lung cancer presented 44 months (median) (range 0-1054) in 662 patientspost organ transplantation. Overall survival was 33%. Death risks were increased forthose who were older (P=0.033) at transplant, diagnosed with small cell lung cancer(P=0.004), and administered with ATG/ALG/OKT_3 (P=0.032) for induction therapy.Surgery (P=0.000) and chemotherapy (P=0.001) were associated with increasedsurvival. Stage makes difference in survival time in recipients (P=0.000). Nodifferences in death risk for age at diagnoses, gender, race, time from transplantationto diagnosis, donor type, transplantation organ and other immunosuppression wereidentified.
Conclusion
1. Lung cancer takes rapid progress and grim outcome under immunosuppression.
2. Death risk was increased for patients with older age at transplantation, histology ofsmall cell lung cancer, induction therapy with ATG/ALG/OKT_3 and later stage oftumor.
3. Death risk was improved for those receiving surgery and chemotherapy.
4. We would suggest immunosuppression regulation with discontinuation of antimetabolites, and 25-50％reduction in CNI dose.
5. Close surveillance is needed for the recipients that used to be heavy smokers.
6. Similar registry as IPITTR should be set up in China transplant community forbetter outcome and follow up for the transplant recipients.
ChapterⅡMultivariate risk factors survival analysis of pre-existing lungcancer in organ transplant recipients
Objective To investigate the risk factors that influence survival of pre-existing lungcancer in organ transplant recipients
Methods Multivariate risk factors survival analysis of pre-existing lung cancer inorgan transplant recipients reported to the Israel Penn International Transplant TumorRegistry from November 1968 to December 2006 was performed.
Results The IPITTR has reviewed a series of 28 cases of pre-existing lung cancer intransplant recipients. Stage data were not included for analysis because of incompleterecords. No differences in death risk for age at diagnoses or transplantation, gender,race, wait time from diagnosis to transplantation, donor type, transplantation organand immunosuppression agents were identified. Recurrences in 6 (21％) patientsoccurred within 5 years post transplantation. 9 patients died within 5 years. Overallsurvival was 68％and mortality was 32％.
Conclusion
1. In literature, transplantation is generally acceptable for only patients with earlystage disease. Overall survival rate has not been good.
2. Survival cures of lung cancer do not begin to flatten until 5 years post diagnosis ingeneral populations. We would recommend 5 years of disease free prior totransplantation.
引文
1. Margreiter R, Kramer R, Huber C, et al. Combined liver and kidney transplantation[J]. Lancet, 1984, 1: 1077-1078.
2．于立新，叶启发，姚冰，等．肝肾联合移植的解剖学基础及临床应用[J]．中国临床解剖学杂志，2001，19：365-366．
3．刘小友，于立新．肝、肾联合移植的适应证[J]．中华器官移植杂志，2000，21：319-320．
4. Demirci G, Becker T, Nyybata M, et al. Results of combined and sequential liver-kidney transplantation[J]. Liver Transpl. 2003, 9: 1067-1078.
5. Abbas Rana, Mark J. Russo, Piotr Witkowski, et al. The Effect of Multi-Organ (Liver/Kidney and Heart/Kidney) Transplants on Kidney Allograft Rejection as Compared to Kidney Transplant Alone: An Analysis of the UNOS Database. American Transplant Congress 2007.
6．朱晓峰，何晓顺，陈规划，陈立中，黄洁夫．肝肾联合移植13例临床总结[J]．中华器官移植杂志，2005，26：415-416．
7．于立新，徐健，邓文锋，等．高龄肝肾联合移植的基础及临床研究(附1例报告)[J]．第一军医大学学报，2003，23：972-973．
8．郑树森．肝肾联合移植的移植部位和布局[J]．中国现代手术学杂志，2001，5：5-6。
9．郑树森．肝肾联合移植二例报告[J]．中国器官移植杂志，2000，21：49-51．
10. Pratima Sharma, Jorge Rakela. Management of pre-liver transplantation patient[J]. Liver Transplantation, 2005, 11: 249-260.
11. Clemmesen JO, Larsen FS, Kondrup J. et al. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration[J]. Hepatology 1999, 29: 648-653.
12. J. Pirenne, D. Monbaliu, D. Kuypers, et al. Survival after Liver Transplantation (LTx) Versus Combined Liver plus Thoracic or Abdominal Organs. American Transplant Congress 2007.
13. Torregrosa JV, Inigo P, Navasa M, et al. Combined liver-kidney transplantation: our experience[J]. Transplant Proc, 1999, 31: 2308-2308.
14. Sepechtenhauser B, Hochletinr B W, Konigsrainer A, et al. Combined liver-kidney transplantation: a single-center report[J]. Transplant Proc, 1999, 31: 3177-3180.
15．肖卫东，吴伟顶，彭承宏，等．临床肝肾联合移植的若干问题[J]．外科理论与实践，2004，9：159-161．
1. Margreiter R, Kramer R, Huber C, et al. Combined liver and kidney transplantation[J]. Lancet, 1984, 1: 1077-1078.
2. Rasmussen A, Davies HS, Jamieson NV, et al. Combined transplantation of liver and kidney from the same donor protects the kidney from rejection and improves kidney graft survival[J]. Transplantation 1995; 59: 919-921.
3. Eid A, Moore SB, Wiesner RH, et al. Evidence that the liver does not always protect the kidney from hyperacute rejection in combined liver-kidney transplantation across a positive lymphocyte crossmatch[J]. Trasnplantation 1990; 50: 331-334.
4．于立新，叶启发，姚冰，等．肝肾联合移植的解剖学基础及临床应用[J]．中国临床解剖学杂志，2001，19：365-366．
5. NYBoom H, Mallat MJ K, De Fijter JW, et al. Delayed graft function influences renal function but not survival[J]. Kidney Int, 2000, 58: 859-866
6. Calne RY, Sells RA, Pena JR, et al. Induction of immunological tolerance by porcine liver allografts[J]. Nature 1969; 223: 472.
7. Kamada N. The immunology of experimental liver transplantation in the rat.[J]Immunology 1985; 55: 369-389.
8. Doyle HR, Marino IR, Morelli F, et al. Assessing risk in liver transplantation special reference to the significance of a positive cytotoxic crossmatch[J]. Ann Surg. 1996; 224: 168-177.
9. Sumimoto R, Kamada N. Specific suppression of allograft rejection by soluble class Ⅰ antigen and complexes with monoclonal antibody[J]. Transplantation. 1990; 50(4): 678-682
10. Morrissey PE, Gordon F, Shaffer D, et al. Combined liver-kidney transplantation in patients with cirrhosis and renal failure: effect of a positive crossmatch and benefits of combined transplantation[J]. Liver Transpl Surg. 1998; 4(5): 363-369.
11. Lang M, Neumann U, Kahl A, et al. Combined liver and kidney transplantation: indications and long-term follow up[J]. Chirurg. 2001; 72(10): 1154-1159.
12. Starzl TE, Demetris AJ, Trucco M, et al. Systemic chimerism in human female recipients of male livers[J]. Lancet 1992; 340: 876-877.
13．刘小友，于立新．肝、肾联合移植的适应证[J]．中华器官移植杂志，2000，21：319-320．
14. Demirci G, Becker T, Nyybata M, et al. Results of combined and sequential liver-kidney transplantation.[J] Liver Transpl. 2003, 9: 1067-1078.
15．朱晓峰，何晓顺，陈规划，陈立中，黄洁夫．肝肾联合移植13例临床总结[J]．中华器官移植杂志，2005，26：415-416．
16. Sanchez EQ, Gonwa TA, Levy MF, et, al. Preoperative and perioperative predictors of the need for renal replacement therapy after orthotopic liver transplantation[J]. Transplantation, 2004, 7: 1048-1054.
17．于立新，徐健，邓文锋，等．高龄肝肾联合移植的基础及临床研究(附1例报告)[J]．第一军医大学学报，2003，23：972-973．
18．肖卫东，吴伟顶，彭承宏，等．临床肝肾联合移植的若干问题[J]．外科理论与实践，2004，9：159-161．
1.Peto R, Chen ZM, Boreham J. Tobacco-the growing epidemic[J]. Nat Med 1999;5:15.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004[J]. CA Cancer J Clin 2004;54:8.
3. Bray F, Tyczynski JE, Parkin DM. Going up or coming down? The changing phases of the lung cancer epidemic from 1967 to 1999 in the 15 European Union countries[J]. Eur J Cancer 2004;40:96.
4. Zhang H, Cai B. The impact of tobacco on lung health in china[J]. Respirology 2003;8:17.
5. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function[J]. Kidney Int 2000; 57: 307.
6. Taylor DO, Edwards LB, Boucek MM, et al. The registry of the International Society for Heart and Lung Transplantation: Twenty-First Official Adult Heart Transplant Report-2004[J]. J Heart Lung Transplant 2004; 23: 796.
7. Rogers C, Alloway R, Boardman R. Global cardiovascular risk under early steroid cessation decreases progressively in the first year post transplant[J]. Am J Transplant 2004; 8: 299.
8. Buell J, Hanaway M, Thomas M, et al. Malignancies associated with liver transplantation [J]. In: Busuttil RW, Klintmalm GB, ed. Transplantation of the liver. Philadelphia: W.B. Saunders, 2004.
9. Buell J, Gross T, Beebe T, et al. Cancer after renal transplantation[J]. In: Cohen EP, ed. Cancer and the kidney. New York City: Oxford University Press, 2004.
10. Buell J, Hanaway M, Thomas M, et al. Malignancies associated with liver transplantation[J]. In: Busuttil RW, Klintmalm GB, ed. Transplantation of the liver. Philadelphia: W.B. Saunders, 2004.
11. Buell J, Gross T, Beebe T, et al. Cancer after renal transplantation. In: Cohen EP, ed. Cancer and the kidney [J]. New York City: Oxford University Press, 2004.
12. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients [J]. In: Terasaki PI, ed. Clinical Transplants. 1998:147-158.3.
13. Penn I. Post-transplant malignancies [J]. Transplant Proc. 1999;31:1260-1262.
14. Gaston RS, Alveranga DY, Becker BN, et al. Kidney and pancreas transplantation[J]. Am J Transplant 2003; 3 (suppl 4): 64.
15. Penn I. Cancers in renal transplant recipients[J] . Adv Ren Replace Ther 2000; 7: 147.
16. Penn I. Post-transplant malignancy: the role of immunosuppression[J]. Drug Saf 2000; 23: 101.
17. Zahoor Ahmed, M. Blair Marshall, John C. Kucharczuk, et al. Lung cancer in transplant recipient[J]. Arch Surg. 2004;139:902.
18. de Perrot M, Wigle DA, Pierre AF, et al. Bronchogenic carcinoma after solid organ transplantation[J]. Ann Thorac Surg. 2003;75:367-371.
19. Delcambre F, Pruvot FR, Ramon P, et al. Primary bronchogenic carcinoma in transplant recipients [J]. Transplant Proc. 1996;28:2884-2885.
20. Goldstein DJ, Williams DL, Oz MC, et al. De novo solid malignancies after cardiac transplantation[J]. Ann Thorac Surg. 1995;60:1783-1789.
21. Fleming RH, Jennison SH, Naunheim KS. Primary bronchogenic carcinoma in the heart transplant recipient[J]. Ann Thorac Surg. 1994;57:1300-1301.
22. Pham SM, Kormos RL, Landreneau RJ, et al. Solid tumors after heart transplantation: lethality of lung cancer[J]. Ann Thorac Surg. 1995;60:1623-1626. 23.Curtil A, Robin J, Tronc F, et al. Malignant neoplasms following cardiac transplantation[J]. Eur J Cardiothorac Surg. 1997;12:101-106.
24. Taniguchi S, Cooper DK, Chaffin JS, Zuhdi N. Primary bronchogenic carcinoma in recipients of heart transplants [J]. Transpl Int. 1997;10:312-316.
25. Couetil JP, McGoldrick JP, Wallwork J. Malignant tumors after heart transplantation[J]. J Heart Transplant. 1990;9:622-626.
26. Collins J, Kazerooni EA, Lacomis J, et al. Bronchogenic carcinoma after lung transplantation: frequency, clinical characteristics, and imaging findings[J]. Radiology. 2002;224:131-138.
27. Stagner LD, Allenspach LL, Hogan KK, et al. Bronchogenic carcinoma in lung transplant recipients [J]. J Heart Lung Transplant. 2001;20:908-911.
28. Arcasoy SM, Hersh C, Christie JD, et al. Bronchogenic carcinoma complicating lung transplantation[J]. J Heart Lung Transplant. 2001;20:1044-1053.
29. Anyanwu AC, Townsend ER, Banner NR, et al. Primary lung carcinoma after heart or lung transplantation: management and outcome[J]. J Thorac Cardiovasc Surg.2002; 124:1190-1197.
30. Choi YH, Leung AN, Miro S, et al. Primary bronchogenic carcinoma after heart or lung transplantation: radiologic and clinical findings[J]. J Thorac Imaging. 2000; 15:36-40
31. Jennifer Trofe, Joseph F. Buell, Thomas M. Beebe, et al. Analysis of factors that influence survival with post-transplantat lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry Experience[J]. Am J Transplant. 2005;5:775.
32. Buell J, Hanaway M, Thomas M, et al. Malignancies associated with liver transplantation. In: Busuttil RW, Klintmalm GB, ed. Transplantation of the liver. Philadelphia: W.B. Saunders, 2004.
33. Swinnen LJ, Fisher RI. OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause of lymphoproliferative disorders associated with transplantation[J]. Curr Opin Nephrol Hypertens 1993; 2: 670.
35. Lenner R, Padilla ML, Teirstein AS, et al. Pulmonary complications in cardiac transplant recipients [J]. Chest 2001; 120: 508.
36. Cherikh WS, KauffmanHM,McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation[J]. Transplantation 2003; 76: 1289.
37. Duvoux C, Pageaux GP, Vanlemmens C, et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients[J]. Transplantation 2002; 74: 1103.
38. Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation[J]. Transplantation 2004; 77: 1777.
39. Reichenspurner H. Overview of tacrolimus-based immunosuppression after heart or lung transplantation[J]. J Heart Lung Transplant 2005; 24: 119.
40. Herman M, Weinstein T, Korzets A, et al. Effect of Cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients [J]. J Lab Clin Med 2001; 137: 14.
41. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism[J]. Nature 1999; 397: 530.
42. Shihab FS, Bennett WM, Isaac J, et al. Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephro toxicity [J]. Kidney Int 2003; 63: 522.
43. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression[J]. Transplantation 2003; 76: 597.
44. Sakai M, Miyake H, Tashiro S, et al. Inhibitory effect of FK506 and cyclosporine A on the growth and invasion of human liver cancer cells[J]. J Med Invest 2004; 51: 63.
45. Dharnidharka VR, Ho PL, Stablein DM, et al. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study[J]. Pediatr Transplant 2002; 6: 396.
46. Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation[J]. Transplantation 2004; 77: 1777.
47. Dharnidharka VR, Ho PL, Stablein DM, et al. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study[J]. Pediatr Transplant 2002; 6: 396.
48. Taylor L, Hughes RA, McPherson K. The risk of cancer from azathioprine as a treatment for multiple sclerosis[J]. Eur J Neurol 2004; 11: 141.
49. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States [J]. Am J Transplant 2004; 4: 905.
50. Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine[J]. Science 1996; 273: 1109.
51. Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation[J]. Blood 2004; 104:822.
52. Tressler RJ, Garvin LJ, Slate DL. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo[J]. Int J Cancer 1994; 57:568.
53. Weber G, Hager JC, Lui MS, et al. Biochemical programs of slowly and rapidly growing human colon carcinoma xenografts. Cancer Res 1981; 41: 854. 58. Natsumeda Y, Prajda N, Donohue JP, et al. Enzymic capacities of purine de novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues[J]. Cancer Res 1984; 44: 2475.
54. Nagai M, Natsumeda Y, Konno Y, et al. Selective up-regulation of type II inosine 5=-monophosphate dehydrogenase messenger RNA expression in human leukemias[J]. Cancer Res 1991; 51: 3886.
55. Weber G, Hager JC, Lui MS, et al. Biochemical programs of slowly and rapidly growing human colon carcinoma xenografts [J]. Cancer Res 1981; 41: 854.
56 Jackson RC, Weber G, Morris HP. IMP dehydrogenase, an enzyme linked with proliferation and malignancy [J]. Nature 1975; 256: 331.
57. Yu J, Lemas V, Page T, et al. Induction of erythroid differentiation in K562 cells by inhibitors of inosine monophosphate dehydrogenase[J]. Cancer Res 1989; 49: 5555.
58. Ohsugi Y, Suzuki S, Takagaki Y. Antitumor and immunosuppressive effects of mycophenolic acid derivatives [J]. Cancer Res 1976; 36: 2923.
59. Carter SB, Franklin TJ, Jones DF, et al. Mycophenolic acid: an anticancer compound with unusual properties [J]. Nature 1969; 223: 848.
60. Engl T, Makarevic J, Relja B, et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy [J]. BMC Cancer 2005; 5: 4.
61. Wang K, Zhang H, Li Y, et al. Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review[J]. Transplant Proc 2004; 36: 2068.
62. Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis[J]. Kidney Int 2003; 63: 917.
63. Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas[J]. Cancer Res 2003; 63: 4472.
64. Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas[J]. Cancer Res 2003; 63: 4472.
65. Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas[J]. Cancer Res 2003; 63: 4472.
66. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor[J]. Nat Med 2002; 8: 128.
67. Buck E, Eyzaguirre A, Brown E, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors[J]. Mol Cancer Ther. 2006 Nov;5(11):2676-84.
68. Trotter JF. Sirolimus in liver transplantation[J]. Transplant Proc 2003; 35:193S.
69. Cherikh WS, KauffmanHM,McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation[J]. Transplantation 2003; 76: 1289.
70. Huang J. Ethical and legislative perspectives on liver transplantation in the People's Republic of China[J]. Liver Transpl. 2007;13:193-6.
1. Abrahams NA, Meziane M, Ramalingam P, et al. Incidence of primary neoplasms in explanted lungs: long-term follow-up from 214 lung transplant patients[J]. Transplant Proc. 2004 Nov;36(9):2808-2811.
2. Denton MD, Magee CC, Ovuworie C, et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis[J]. Kidney Int 2002; 61: 2201.
3 Marc de Perrot, Susan Chernenko, Thomas K et al. Role of lung transplantation in the treatment of bronchogenic carcinomas for patients with end-stage pulmonary disease[J]. J Clic Oncol. 2004,22:4351-4356
4. Compton C, Fenoglio-Preiser CM, Pettigrew N, et al American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group[J]. Cancer. 2000 1;88(7): 1739-57
1. Penn I. Cancers in renal transplant recipients[J]. Adv Ren Replace Ther 2000; 7: 147.
2. Penn I. Post-transplant malignancy: the role of immunosuppression[J]. Drug Saf 2000; 23: 101.
3. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. In: Cecka JM, Terasaki PI, eds. Clinical Transplant 1998. Los Angeles: UCLA Tissue Typing Laboratory, 1998: 147.
4. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function[J]. Kidney Int 2000; 57: 307
5. Taylor DO, Edwards LB, Boucek MM, et al. The registry of the International Society for Heart and Lung Transplantation: Twenty-First Official Adult Heart Transplant Report-2004[J]. J Heart Lung Transplant 2004; 23: 796.
6. Rogers C, Alloway R, Boardman R. Global cardiovascular risk under early steroid cessation decreases progressively in the first year post transplant[J]. Am J Transplant 2004; 8: 299.)
7. Buell J, Gross T, Beebe T, et al. Cancer after renal transplantation. In: Cohen EP, ed. Cancer and the kidney. New York City: Oxford University Press, 2004.
8. Buell J, Hanaway M, Thomas M, et al. Malignancies associated with liver transplantation. In: Busuttil RW, Klintmalm GB, ed. Transplantation of the liver[J]. Philadelphia: W.B. Saunders, 2004.
9. Buell J, Gross T, Beebe T, et al. Cancer after renal transplantation. In: Cohen EP, ed. Cancer and the kidney[J]. New York City: Oxford University Press, 2004.
10. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients [J]. In: Terasaki PI, ed. Clinical Transplants. 1998:147-158.3.
11. Penn I. Post-transplant malignancies [J]. Transplant Proc. 1999;31:1260-1262.
12. Gaston RS, Alveranga DY, Becker BN, et al. Kidney and pancreas transplantation[J].Am J Transplant 2003; 3 (suppl 4): 64.
13. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients[J]. In: Terasaki PI, ed. Clinical Transplants. 1998:147-158.3.
14. Penn I. Cancers in renal transplant recipients [J]. Adv Ren Replace Ther 2000; 7: 147.
15. Chapman J, Webster AC. Cancer report: ANZDATA Registry 2004 report[J], 2004: 99.
16. Hiesse C, Rieu P, Kriaa F, et al. Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period[J]. Transplant Proc 1997; 29: 831.
17. Winkelhorst JT, Brokelman WJ, Tiggeler RG, Wobbes T. Incidence and clinical course of de-novo malignancies in renal allograft recipients [J].Eur J Surg Oncol 2001; 27: 409.
18. Hartevelt MM, Bavinck JN, Kootte AM, et al. Incidence of skin cancer after renal transplantation in the Netherlands [J]. Transplantation 1990; 49: 506.
19. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens [J]. J Am Acad Dermatol 1999; 40: 177.
20. Ramsay HM, Fryer AA, Hawley CM, et al. Non-melanoma skin cancer risk in the Queensland renal transplant population[J]. Br J Dermatol 2002; 147: 950.
21. Bordea C, Wojnarowska F, Millard PR, et al. Skin cancers in renal transplant recipients occur more frequently than previously recognized in a temperate climate[J]. Transplantation 2004; 77: 574.
22. Penn I. Posttransplantation de novo tumors in liver allograft recipients [J]. Liver Transpl Surg 1996; 2: 52.
23. Shiba N, Chan MC, Kwok BW, et al. Analysis of survivors more than 10 years after heart transplantation in the cyclosporine era: Stanford experience [J]. J Heart Lung Transplant 2004; 23: 155.
24. Stewart JH, Buccianti G, Agodoa L, et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand[J]. J Am Soc Nephrol 2003; 14: 197.
25. Denton MD, Magee CC, Ovuworie C, et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis [J]. Kidney Int 2002; 61: 2201.
26. National Institute of Diabetes and Digestive and Kidney Diseases. Hepatocellular carcinoma: Screening, diagnosis and management, 2004. Available at www.niddk.nih.gov/fund/other/hepato_carc/liver_cancer. Accessed July 1, 2005.
27. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C[J]. Liver Transpl 2003; 9 (Suppl): S1.
28. Fong Y, Kemeny N, Lawrence TS. Cancer of the liver and biliary tree. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and practice of oncology[J]. Philadelphia: Lippincott Williams & Wilkins, 2001: 1162.
29. Coit DG. Cancer of the small intestine. In: DeVita VT, Hellman S,Rosenberg SA, eds. Cancer: Principles and practice of oncology[J]. Philadelphia: Lippincott Williams & Wilkins, 2001: 1204.
30. Yarchoan R, Little RF. Immunosuppression-related malignancies. In:DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and practice of oncology[J]. Philadelphia: Lippincott Williams & Wilkins, 2001:2575.
31. Rosenberg S. Principles of cancer management: Biologic therapy. In: DeVita VT, Hellman S, Rosenberg SA, ed. Cancer: Principles and practicesof oncology[J]. Philadelphia: Lippincott Williams & Wilkins, 2001:307.
32. Diehl V, Hauch P, Harris N. Hodgkin's Disease. In: DeVita VT, Hellman S, Rosenberg SA, ed. Cancer: Principles and practice of oncology[J]. Philadelphia: Lippincott Williams & Wilkins, 2001: 2339.
33. Alamartine E, Sabido O, Berthoux F. In-vitro effects of Cyclosporin A,FK506, 6-mercaptopurine, and prednisolone on lymphokine-activated killer cells[J]. Nephrol Dial Transplant 1994; 9: 1456.
34. Tamura F, Masuhara A, Sakaida I, et al. FK506 promotes liver regeneration by suppressing natural killer cell activity[J]. J Gastroenterol Hepatol 1998; 13: 703.
35. Fung JJ, Jain A, Kwak EJ, et al. De novo malignancies after liver transplantation: a major cause of late death[J]. Liver Transpl 2001; 7 (Suppl):S109.
36. Engels EA, Goedert JJ. Human immunodeficiency virus/acquired immunodeficiency syndrome and cancer: past, present, and future[J]. J Natl Cancer Inst 2005; 97: 407.
37. Muller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology[J]. Ann Hematol2005;84: 1.
38. Moore PS, Gao SJ, Dominguez G, et al. Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae[J]. J Virol 1996; 70: 549.
39. Penn I. Kaposi's sarcoma in transplant recipients [J]. Transplantation 1997; 64: 669.
40. Woodle ES, Hanaway M, Buell J, et al. Kaposi sarcoma: an analysis of the US and international experiences from the Israel Penn International Transplant Tumor Registry[J]. Transplant Proc 2001; 33: 3660.
41. Meyer T, Arndt R, Nindl I, et al. Association of human papillomavirus infections with cutaneous tumors in immunosuppressed patients[J]. Transpl Int 2003; 16: 146.
42. Euvrard S, Chardonnet Y, Pouteil-Noble C, et al. Association of skin malignancies with various and multiple carcinogenic and noncarcinogenic human papillomaviruses in renal transplant recipients [J]. Cancer 1993; 72: 2198.
43. Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation[J]. Transplantation 2004; 77: 1777.
44. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism[J]. Nature 1999; 397: 530.
45. Shihab FS, Bennett WM, Isaac J, et al. Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephro toxicity [J]. Kidney Int 2003; 63: 522.
46. Reichenspurner H. Overview of tacrolimus-based immunosuppression after heart or lung transplantation[J]. J Heart Lung Transplant 2005; 24: 119.
47. Herman M, Weinstein T, Korzets A, et al. Effect of Cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients [J]. J Lab Clin Med 2001; 137: 14.
48. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism[J]. Nature 1999; 397: 530.
49. Shihab FS, Bennett WM, Isaac J, et al. Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity[J]. Kidney Int 2003; 63: 522.
50. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression[J]. Transplantation 2003; 76: 597.
51. Sakai M, Miyake H, Tashiro S, et al. Inhibitory effect of FK506 and cyclosporine A on the growth and invasion of human liver cancer cells[J]. J Med Invest 2004; 51: 63.
52. Dharnidharka VR, Ho PL, Stablein DM, et al. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study[J]. Pediatr Transplant 2002; 6: 396.
53. Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation[J]. Transplantation 2004; 77: 1777.
54. Dharnidharka VR, Ho PL, Stablein DM, et al. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study [J]. Pediatr Transplant 2002; 6: 396.
55. Taylor L, Hughes RA, McPherson K. The risk of cancer from azathioprine as a treatment for multiple sclerosis [J]. Eur J Neurol 2004; 11: 141.
56. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States[J]. Am J Transplant 2004; 4: 905.
57. Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine[J]. Science 1996; 273: 1109.
58. Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation[J]. Blood 2004; 104: 822.
59. Tressler RJ, Garvin LJ, Slate DL. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo[J]. Int J Cancer 1994; 57:568.
60. Weber G, Hager JC, Lui MS, et al. Biochemical programs of slowly and rapidly growing human colon carcinoma xenografts. Cancer Res 1981; 41: 854. 58. Natsumeda Y, Prajda N, Donohue JP, et al. Enzymic capacities of purine de novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues [J]. Cancer Res 1984; 44: 2475.
61. Nagai M, Natsumeda Y, Konno Y, et al. Selective up-regulation of type II inosine 5=-monophosphate dehydrogenase messenger RNA expression in human leukemias[J]. Cancer Res 1991; 51: 3886.
62. Weber G, Hager JC, Lui MS, et al. Biochemical programs of slowly and rapidly growing human colon carcinoma xenografts [J]. Cancer Res 1981; 41: 854.
63. Jackson RC, Weber G, Morris HP. IMP dehydrogenase, an enzyme linked with proliferation and malignancy [J]. Nature 1975; 256: 331.
64. Yu J, Lemas V, Page T, et al. Induction of erythroid differentiation in K562 cells by inhibitors of inosine monophosphate dehydrogenase [J]. Cancer Res 1989; 49: 5555.
65. Ohsugi Y, Suzuki S, Takagaki Y. Antitumor and immunosuppressive effects of mycophenolic acid derivatives [J]. Cancer Res 1976; 36: 2923.
66. Carter SB, Franklin TJ, Jones DF, et al. Mycophenolic acid: an anticancer compound with unusual properties[J]. Nature 1969; 223: 848.
67. Engl T, Makarevic J, Relja B, et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy [J]. BMC Cancer 2005; 5: 4.
68. Wang K, Zhang H, Li Y, et al. Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review[J]. Transplant Proc 2004; 36: 2068.
69. Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis[J]. Kidney Int 2003; 63: 917.
70. Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas[J]. Cancer Res 2003; 63: 4472.
71. Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas[J]. Cancer Res 2003; 63: 4472.
72. Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas[J]. Cancer Res 2003; 63: 4472.
73. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor[J]. Nat Med 2002; 8: 128.
74. Buck E, Eyzaguirre A, Brown E, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors[J]. Mol Cancer Ther. 2006 Nov;5(11):2676-84.
75. Trotter JF. Sirolimus in liver transplantation[J]. Transplant Proc 2003; 35:193S
76. Yakupoglu Y, Knight R, Katz S. Low incidence of malignancy among sirolimus-cyclosporine treated transplant recipients[J]. Am J Transplant 2004; 3 (Suppl 5): 187.
77. Kahan B, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience [J]. Transplant Proc 2003; 35: 25S.
78. Swinnen LJ, Fisher RI. OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause of lymphoproliferative disorders associated with transplantation [J]. Curr Opin Nephrol Hypertens 1993; 2: 670.
79. Lenner R, Padilla ML, Teirstein AS, et al. Pulmonary complications in cardiac transplant recipients [J]. Chest 2001; 120: 508.
80. Cherikh WS, KauffmanHM,McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation [J]. Transplantation 2003; 76: 1289.
81. Ruiz P, Soares MF, Garcia M, et al. Lymphoplasmacytic hyperplasia(possibly pre-PTLD) has varied expression and appearance in intestinal transplant recipients receiving Campath immunosuppression[J]. Transplant Proc 2004; 36: 386.
82. Kovarik JM, Schmouder RL, Slade AJ. Overview of FTY720 clinical pharmacokinetics and pharmacology. Ther Drug Monit 2004; 26: 585.
83. Ueda H, Takahara S, Itoh S, et al. Preoperative administration of FTY720 prolonged renal allograft survival[J]. Transpl Immunol 2005; 14:453
84. Naparstek E. The role of the anti-CD20 antibody rituximab in hematopoietic stem cell transplantation for non-Hodgkin's lymphoma[J]. CurrHematol Rep 2005; 4: 276.
85. Shroff R, Rees L. The post-transplant lymphoproliferative disorder-a literature review[J]. Pediatr Nephrol 2004; 19: 369.
86. Cao S, Cox K, Esquivel CO, et al. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation[J]. Transplantation 1998; 66: 851.
87. Dotti G, Fiocchi R, Motta T, et al. Epstein-Barr virus-negative lymphoproliferative disorders in long-term survivors after heart, kidney, and liver transplant[J]. Transplantation 2000; 69: 827.
88. Aull MJ, Buell JF, Trofe J, et al. Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry[J]. Transplantation 2004; 78: 1676.
89. Merchen T, Gupta M, First MR, et al. PTLD following lung transplantation [Abstract]. Am J Transplant 2003; 3: 157.
90. Hanaway MJ, Buell JF, Woodle ES, et al. Effect of sites of presentation of PTLD markedly influences survival after solid organ transplantation [J]. Am J Transplant 2004; 8: 521.
91. Castellano-Sanchez AA, Li S, Qian J, et al. Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol 2004; 121: 246.
92. Hanaway M, Buell J, Woodle E, et al. Effect of PTLD-sites of presentation on survival after liver transplantation[J]. Liver Transpl 2003; 9: C33.
93. Buell JF, Gross TG, Hanaway MJ, et al. Post transplant lymphoproliferative disorder: the significance of central nervous system involvement [Abstract]. Am J Transplant 2002; 2: 373.
94. Gross T. Low-dose chemotherapy for children with post-transplant lymphoproliferative disease[J]. Recent Results Cancer Res 2002; 159: 96.
95. Pescovitz M, Funch D, Schneider G, Walker A. Antiviral use and its association with post-transplant lymphoproliferative disorder (PTLD) in renal transplant patients[J]. Am J Transplant 2003; 3: 447.
96. Humar A, Hebert D, Davies D, et al. A multi-center randomized trial of ganciclovir vs. ganciclovir plus immune globulin for prophylaxis against EBV related PTLD in high risk solid organ transplant recipients: one-year results [Abstract]. Am J Transplant 2003; 3: 446.
97. Niitsu N, Hayama M, Okamoto M, et al. Phase I study of rituximab- CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma[J]. Clin Cancer Res 2004; 10: 4077.
98. Mellstedt H. Monoclonal antibodies in human cancer[J]. Drugs Today (Barc) 2003; 39 (Suppl C): 1.
99. Ganne V, Siddiqi N, Kamaplath B, et al. Humanized anti-CD20 monoclonal antibody (rituximab) treatment for post-transplant lymphoproliferative disorder [J]. Clin Transplant 2003; 17: 417.
100. Jain A. Single center experience with rituximab for the treatment of PTLD in transplant recipients [J]. Am J Transplant 2003; 3: 446.
101. Orjuela M, Gross TG, Cheung YK, et al. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation[J]. Clin Cancer Res 2003; 9 (Suppl): 3945S.
102. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation[J]. N Engl J Med 2003; 348: 1681.
103. Dreno B, Mansat E, Legoux B, Litoux P. Skin cancers in transplant patients[J]. Nephrol Dial Transplant 1998; 13: 1374.
104. Gupta AK, Cardella CJ, Haberman HF. Cutaneous malignant neoplasms in patients with renal transplants [J]. Arch Dermatol 1986; 122: 1288.
105. Penn I, Brunson ME. Cancers after cyclosporine therapy. Transplant Proc 1988; 20:885.) [J]
106. Ulrich C, Schmook T, Sachse MM, et al. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients [J]. Dermatol Surg 2004; 30: 622.
2．于立新，叶启发，姚冰，等．肝肾联合移植的解剖学基础及临床应用[J]．中国临床解剖学杂志，2001，19：365-366．
3．刘小友，于立新．肝、肾联合移植的适应证[J]．中华器官移植杂志，2000，21：319-320．
4. Demirci G, Becker T, Nyybata M, et al. Results of combined and sequential liver-kidney transplantation[J]. Liver Transpl. 2003, 9: 1067-1078.
5. Abbas Rana, Mark J. Russo, Piotr Witkowski, et al. The Effect of Multi-Organ (Liver/Kidney and Heart/Kidney) Transplants on Kidney Allograft Rejection as Compared to Kidney Transplant Alone: An Analysis of the UNOS Database. American Transplant Congress 2007.
6．朱晓峰，何晓顺，陈规划，陈立中，黄洁夫．肝肾联合移植13例临床总结[J]．中华器官移植杂志，2005，26：415-416．
7．于立新，徐健，邓文锋，等．高龄肝肾联合移植的基础及临床研究(附1例报告)[J]．第一军医大学学报，2003，23：972-973．
8．郑树森．肝肾联合移植的移植部位和布局[J]．中国现代手术学杂志，2001，5：5-6。
9．郑树森．肝肾联合移植二例报告[J]．中国器官移植杂志，2000，21：49-51．
10. Pratima Sharma, Jorge Rakela. Management of pre-liver transplantation patient[J]. Liver Transplantation, 2005, 11: 249-260.
11. Clemmesen JO, Larsen FS, Kondrup J. et al. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration[J]. Hepatology 1999, 29: 648-653.
12. J. Pirenne, D. Monbaliu, D. Kuypers, et al. Survival after Liver Transplantation (LTx) Versus Combined Liver plus Thoracic or Abdominal Organs. American Transplant Congress 2007.
13. Torregrosa JV, Inigo P, Navasa M, et al. Combined liver-kidney transplantation: our experience[J]. Transplant Proc, 1999, 31: 2308-2308.
14. Sepechtenhauser B, Hochletinr B W, Konigsrainer A, et al. Combined liver-kidney transplantation: a single-center report[J]. Transplant Proc, 1999, 31: 3177-3180.
15．肖卫东，吴伟顶，彭承宏，等．临床肝肾联合移植的若干问题[J]．外科理论与实践，2004，9：159-161．
1. Margreiter R, Kramer R, Huber C, et al. Combined liver and kidney transplantation[J]. Lancet, 1984, 1: 1077-1078.
2. Rasmussen A, Davies HS, Jamieson NV, et al. Combined transplantation of liver and kidney from the same donor protects the kidney from rejection and improves kidney graft survival[J]. Transplantation 1995; 59: 919-921.
3. Eid A, Moore SB, Wiesner RH, et al. Evidence that the liver does not always protect the kidney from hyperacute rejection in combined liver-kidney transplantation across a positive lymphocyte crossmatch[J]. Trasnplantation 1990; 50: 331-334.
4．于立新，叶启发，姚冰，等．肝肾联合移植的解剖学基础及临床应用[J]．中国临床解剖学杂志，2001，19：365-366．
5. NYBoom H, Mallat MJ K, De Fijter JW, et al. Delayed graft function influences renal function but not survival[J]. Kidney Int, 2000, 58: 859-866
6. Calne RY, Sells RA, Pena JR, et al. Induction of immunological tolerance by porcine liver allografts[J]. Nature 1969; 223: 472.
7. Kamada N. The immunology of experimental liver transplantation in the rat.[J]Immunology 1985; 55: 369-389.
8. Doyle HR, Marino IR, Morelli F, et al. Assessing risk in liver transplantation special reference to the significance of a positive cytotoxic crossmatch[J]. Ann Surg. 1996; 224: 168-177.
9. Sumimoto R, Kamada N. Specific suppression of allograft rejection by soluble class Ⅰ antigen and complexes with monoclonal antibody[J]. Transplantation. 1990; 50(4): 678-682
10. Morrissey PE, Gordon F, Shaffer D, et al. Combined liver-kidney transplantation in patients with cirrhosis and renal failure: effect of a positive crossmatch and benefits of combined transplantation[J]. Liver Transpl Surg. 1998; 4(5): 363-369.
11. Lang M, Neumann U, Kahl A, et al. Combined liver and kidney transplantation: indications and long-term follow up[J]. Chirurg. 2001; 72(10): 1154-1159.
12. Starzl TE, Demetris AJ, Trucco M, et al. Systemic chimerism in human female recipients of male livers[J]. Lancet 1992; 340: 876-877.
13．刘小友，于立新．肝、肾联合移植的适应证[J]．中华器官移植杂志，2000，21：319-320．
14. Demirci G, Becker T, Nyybata M, et al. Results of combined and sequential liver-kidney transplantation.[J] Liver Transpl. 2003, 9: 1067-1078.
15．朱晓峰，何晓顺，陈规划，陈立中，黄洁夫．肝肾联合移植13例临床总结[J]．中华器官移植杂志，2005，26：415-416．
16. Sanchez EQ, Gonwa TA, Levy MF, et, al. Preoperative and perioperative predictors of the need for renal replacement therapy after orthotopic liver transplantation[J]. Transplantation, 2004, 7: 1048-1054.
17．于立新，徐健，邓文锋，等．高龄肝肾联合移植的基础及临床研究(附1例报告)[J]．第一军医大学学报，2003，23：972-973．
18．肖卫东，吴伟顶，彭承宏，等．临床肝肾联合移植的若干问题[J]．外科理论与实践，2004，9：159-161．
1.Peto R, Chen ZM, Boreham J. Tobacco-the growing epidemic[J]. Nat Med 1999;5:15.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004[J]. CA Cancer J Clin 2004;54:8.
3. Bray F, Tyczynski JE, Parkin DM. Going up or coming down? The changing phases of the lung cancer epidemic from 1967 to 1999 in the 15 European Union countries[J]. Eur J Cancer 2004;40:96.
4. Zhang H, Cai B. The impact of tobacco on lung health in china[J]. Respirology 2003;8:17.
5. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function[J]. Kidney Int 2000; 57: 307.
6. Taylor DO, Edwards LB, Boucek MM, et al. The registry of the International Society for Heart and Lung Transplantation: Twenty-First Official Adult Heart Transplant Report-2004[J]. J Heart Lung Transplant 2004; 23: 796.
7. Rogers C, Alloway R, Boardman R. Global cardiovascular risk under early steroid cessation decreases progressively in the first year post transplant[J]. Am J Transplant 2004; 8: 299.
8. Buell J, Hanaway M, Thomas M, et al. Malignancies associated with liver transplantation [J]. In: Busuttil RW, Klintmalm GB, ed. Transplantation of the liver. Philadelphia: W.B. Saunders, 2004.
9. Buell J, Gross T, Beebe T, et al. Cancer after renal transplantation[J]. In: Cohen EP, ed. Cancer and the kidney. New York City: Oxford University Press, 2004.
10. Buell J, Hanaway M, Thomas M, et al. Malignancies associated with liver transplantation[J]. In: Busuttil RW, Klintmalm GB, ed. Transplantation of the liver. Philadelphia: W.B. Saunders, 2004.
11. Buell J, Gross T, Beebe T, et al. Cancer after renal transplantation. In: Cohen EP, ed. Cancer and the kidney [J]. New York City: Oxford University Press, 2004.
12. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients [J]. In: Terasaki PI, ed. Clinical Transplants. 1998:147-158.3.
13. Penn I. Post-transplant malignancies [J]. Transplant Proc. 1999;31:1260-1262.
14. Gaston RS, Alveranga DY, Becker BN, et al. Kidney and pancreas transplantation[J]. Am J Transplant 2003; 3 (suppl 4): 64.
15. Penn I. Cancers in renal transplant recipients[J] . Adv Ren Replace Ther 2000; 7: 147.
16. Penn I. Post-transplant malignancy: the role of immunosuppression[J]. Drug Saf 2000; 23: 101.
17. Zahoor Ahmed, M. Blair Marshall, John C. Kucharczuk, et al. Lung cancer in transplant recipient[J]. Arch Surg. 2004;139:902.
18. de Perrot M, Wigle DA, Pierre AF, et al. Bronchogenic carcinoma after solid organ transplantation[J]. Ann Thorac Surg. 2003;75:367-371.
19. Delcambre F, Pruvot FR, Ramon P, et al. Primary bronchogenic carcinoma in transplant recipients [J]. Transplant Proc. 1996;28:2884-2885.
20. Goldstein DJ, Williams DL, Oz MC, et al. De novo solid malignancies after cardiac transplantation[J]. Ann Thorac Surg. 1995;60:1783-1789.
21. Fleming RH, Jennison SH, Naunheim KS. Primary bronchogenic carcinoma in the heart transplant recipient[J]. Ann Thorac Surg. 1994;57:1300-1301.
22. Pham SM, Kormos RL, Landreneau RJ, et al. Solid tumors after heart transplantation: lethality of lung cancer[J]. Ann Thorac Surg. 1995;60:1623-1626. 23.Curtil A, Robin J, Tronc F, et al. Malignant neoplasms following cardiac transplantation[J]. Eur J Cardiothorac Surg. 1997;12:101-106.
24. Taniguchi S, Cooper DK, Chaffin JS, Zuhdi N. Primary bronchogenic carcinoma in recipients of heart transplants [J]. Transpl Int. 1997;10:312-316.
25. Couetil JP, McGoldrick JP, Wallwork J. Malignant tumors after heart transplantation[J]. J Heart Transplant. 1990;9:622-626.
26. Collins J, Kazerooni EA, Lacomis J, et al. Bronchogenic carcinoma after lung transplantation: frequency, clinical characteristics, and imaging findings[J]. Radiology. 2002;224:131-138.
27. Stagner LD, Allenspach LL, Hogan KK, et al. Bronchogenic carcinoma in lung transplant recipients [J]. J Heart Lung Transplant. 2001;20:908-911.
28. Arcasoy SM, Hersh C, Christie JD, et al. Bronchogenic carcinoma complicating lung transplantation[J]. J Heart Lung Transplant. 2001;20:1044-1053.
29. Anyanwu AC, Townsend ER, Banner NR, et al. Primary lung carcinoma after heart or lung transplantation: management and outcome[J]. J Thorac Cardiovasc Surg.2002; 124:1190-1197.
30. Choi YH, Leung AN, Miro S, et al. Primary bronchogenic carcinoma after heart or lung transplantation: radiologic and clinical findings[J]. J Thorac Imaging. 2000; 15:36-40
31. Jennifer Trofe, Joseph F. Buell, Thomas M. Beebe, et al. Analysis of factors that influence survival with post-transplantat lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry Experience[J]. Am J Transplant. 2005;5:775.
32. Buell J, Hanaway M, Thomas M, et al. Malignancies associated with liver transplantation. In: Busuttil RW, Klintmalm GB, ed. Transplantation of the liver. Philadelphia: W.B. Saunders, 2004.
33. Swinnen LJ, Fisher RI. OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause of lymphoproliferative disorders associated with transplantation[J]. Curr Opin Nephrol Hypertens 1993; 2: 670.
35. Lenner R, Padilla ML, Teirstein AS, et al. Pulmonary complications in cardiac transplant recipients [J]. Chest 2001; 120: 508.
36. Cherikh WS, KauffmanHM,McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation[J]. Transplantation 2003; 76: 1289.
37. Duvoux C, Pageaux GP, Vanlemmens C, et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients[J]. Transplantation 2002; 74: 1103.
38. Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation[J]. Transplantation 2004; 77: 1777.
39. Reichenspurner H. Overview of tacrolimus-based immunosuppression after heart or lung transplantation[J]. J Heart Lung Transplant 2005; 24: 119.
40. Herman M, Weinstein T, Korzets A, et al. Effect of Cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients [J]. J Lab Clin Med 2001; 137: 14.
41. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism[J]. Nature 1999; 397: 530.
42. Shihab FS, Bennett WM, Isaac J, et al. Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephro toxicity [J]. Kidney Int 2003; 63: 522.
43. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression[J]. Transplantation 2003; 76: 597.
44. Sakai M, Miyake H, Tashiro S, et al. Inhibitory effect of FK506 and cyclosporine A on the growth and invasion of human liver cancer cells[J]. J Med Invest 2004; 51: 63.
45. Dharnidharka VR, Ho PL, Stablein DM, et al. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study[J]. Pediatr Transplant 2002; 6: 396.
46. Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation[J]. Transplantation 2004; 77: 1777.
47. Dharnidharka VR, Ho PL, Stablein DM, et al. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study[J]. Pediatr Transplant 2002; 6: 396.
48. Taylor L, Hughes RA, McPherson K. The risk of cancer from azathioprine as a treatment for multiple sclerosis[J]. Eur J Neurol 2004; 11: 141.
49. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States [J]. Am J Transplant 2004; 4: 905.
50. Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine[J]. Science 1996; 273: 1109.
51. Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation[J]. Blood 2004; 104:822.
52. Tressler RJ, Garvin LJ, Slate DL. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo[J]. Int J Cancer 1994; 57:568.
53. Weber G, Hager JC, Lui MS, et al. Biochemical programs of slowly and rapidly growing human colon carcinoma xenografts. Cancer Res 1981; 41: 854. 58. Natsumeda Y, Prajda N, Donohue JP, et al. Enzymic capacities of purine de novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues[J]. Cancer Res 1984; 44: 2475.
54. Nagai M, Natsumeda Y, Konno Y, et al. Selective up-regulation of type II inosine 5=-monophosphate dehydrogenase messenger RNA expression in human leukemias[J]. Cancer Res 1991; 51: 3886.
55. Weber G, Hager JC, Lui MS, et al. Biochemical programs of slowly and rapidly growing human colon carcinoma xenografts [J]. Cancer Res 1981; 41: 854.
56 Jackson RC, Weber G, Morris HP. IMP dehydrogenase, an enzyme linked with proliferation and malignancy [J]. Nature 1975; 256: 331.
57. Yu J, Lemas V, Page T, et al. Induction of erythroid differentiation in K562 cells by inhibitors of inosine monophosphate dehydrogenase[J]. Cancer Res 1989; 49: 5555.
58. Ohsugi Y, Suzuki S, Takagaki Y. Antitumor and immunosuppressive effects of mycophenolic acid derivatives [J]. Cancer Res 1976; 36: 2923.
59. Carter SB, Franklin TJ, Jones DF, et al. Mycophenolic acid: an anticancer compound with unusual properties [J]. Nature 1969; 223: 848.
60. Engl T, Makarevic J, Relja B, et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy [J]. BMC Cancer 2005; 5: 4.
61. Wang K, Zhang H, Li Y, et al. Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review[J]. Transplant Proc 2004; 36: 2068.
62. Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis[J]. Kidney Int 2003; 63: 917.
63. Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas[J]. Cancer Res 2003; 63: 4472.
64. Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas[J]. Cancer Res 2003; 63: 4472.
65. Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas[J]. Cancer Res 2003; 63: 4472.
66. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor[J]. Nat Med 2002; 8: 128.
67. Buck E, Eyzaguirre A, Brown E, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors[J]. Mol Cancer Ther. 2006 Nov;5(11):2676-84.
68. Trotter JF. Sirolimus in liver transplantation[J]. Transplant Proc 2003; 35:193S.
69. Cherikh WS, KauffmanHM,McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation[J]. Transplantation 2003; 76: 1289.
70. Huang J. Ethical and legislative perspectives on liver transplantation in the People's Republic of China[J]. Liver Transpl. 2007;13:193-6.
1. Abrahams NA, Meziane M, Ramalingam P, et al. Incidence of primary neoplasms in explanted lungs: long-term follow-up from 214 lung transplant patients[J]. Transplant Proc. 2004 Nov;36(9):2808-2811.
2. Denton MD, Magee CC, Ovuworie C, et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis[J]. Kidney Int 2002; 61: 2201.
3 Marc de Perrot, Susan Chernenko, Thomas K et al. Role of lung transplantation in the treatment of bronchogenic carcinomas for patients with end-stage pulmonary disease[J]. J Clic Oncol. 2004,22:4351-4356
4. Compton C, Fenoglio-Preiser CM, Pettigrew N, et al American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group[J]. Cancer. 2000 1;88(7): 1739-57
1. Penn I. Cancers in renal transplant recipients[J]. Adv Ren Replace Ther 2000; 7: 147.
2. Penn I. Post-transplant malignancy: the role of immunosuppression[J]. Drug Saf 2000; 23: 101.
3. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. In: Cecka JM, Terasaki PI, eds. Clinical Transplant 1998. Los Angeles: UCLA Tissue Typing Laboratory, 1998: 147.
4. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function[J]. Kidney Int 2000; 57: 307
5. Taylor DO, Edwards LB, Boucek MM, et al. The registry of the International Society for Heart and Lung Transplantation: Twenty-First Official Adult Heart Transplant Report-2004[J]. J Heart Lung Transplant 2004; 23: 796.
6. Rogers C, Alloway R, Boardman R. Global cardiovascular risk under early steroid cessation decreases progressively in the first year post transplant[J]. Am J Transplant 2004; 8: 299.)
7. Buell J, Gross T, Beebe T, et al. Cancer after renal transplantation. In: Cohen EP, ed. Cancer and the kidney. New York City: Oxford University Press, 2004.
8. Buell J, Hanaway M, Thomas M, et al. Malignancies associated with liver transplantation. In: Busuttil RW, Klintmalm GB, ed. Transplantation of the liver[J]. Philadelphia: W.B. Saunders, 2004.
9. Buell J, Gross T, Beebe T, et al. Cancer after renal transplantation. In: Cohen EP, ed. Cancer and the kidney[J]. New York City: Oxford University Press, 2004.
10. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients [J]. In: Terasaki PI, ed. Clinical Transplants. 1998:147-158.3.
11. Penn I. Post-transplant malignancies [J]. Transplant Proc. 1999;31:1260-1262.
12. Gaston RS, Alveranga DY, Becker BN, et al. Kidney and pancreas transplantation[J].Am J Transplant 2003; 3 (suppl 4): 64.
13. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients[J]. In: Terasaki PI, ed. Clinical Transplants. 1998:147-158.3.
14. Penn I. Cancers in renal transplant recipients [J]. Adv Ren Replace Ther 2000; 7: 147.
15. Chapman J, Webster AC. Cancer report: ANZDATA Registry 2004 report[J], 2004: 99.
16. Hiesse C, Rieu P, Kriaa F, et al. Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period[J]. Transplant Proc 1997; 29: 831.
17. Winkelhorst JT, Brokelman WJ, Tiggeler RG, Wobbes T. Incidence and clinical course of de-novo malignancies in renal allograft recipients [J].Eur J Surg Oncol 2001; 27: 409.
18. Hartevelt MM, Bavinck JN, Kootte AM, et al. Incidence of skin cancer after renal transplantation in the Netherlands [J]. Transplantation 1990; 49: 506.
19. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens [J]. J Am Acad Dermatol 1999; 40: 177.
20. Ramsay HM, Fryer AA, Hawley CM, et al. Non-melanoma skin cancer risk in the Queensland renal transplant population[J]. Br J Dermatol 2002; 147: 950.
21. Bordea C, Wojnarowska F, Millard PR, et al. Skin cancers in renal transplant recipients occur more frequently than previously recognized in a temperate climate[J]. Transplantation 2004; 77: 574.
22. Penn I. Posttransplantation de novo tumors in liver allograft recipients [J]. Liver Transpl Surg 1996; 2: 52.
23. Shiba N, Chan MC, Kwok BW, et al. Analysis of survivors more than 10 years after heart transplantation in the cyclosporine era: Stanford experience [J]. J Heart Lung Transplant 2004; 23: 155.
24. Stewart JH, Buccianti G, Agodoa L, et al. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand[J]. J Am Soc Nephrol 2003; 14: 197.
25. Denton MD, Magee CC, Ovuworie C, et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis [J]. Kidney Int 2002; 61: 2201.
26. National Institute of Diabetes and Digestive and Kidney Diseases. Hepatocellular carcinoma: Screening, diagnosis and management, 2004. Available at www.niddk.nih.gov/fund/other/hepato_carc/liver_cancer. Accessed July 1, 2005.
27. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C[J]. Liver Transpl 2003; 9 (Suppl): S1.
28. Fong Y, Kemeny N, Lawrence TS. Cancer of the liver and biliary tree. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and practice of oncology[J]. Philadelphia: Lippincott Williams & Wilkins, 2001: 1162.
29. Coit DG. Cancer of the small intestine. In: DeVita VT, Hellman S,Rosenberg SA, eds. Cancer: Principles and practice of oncology[J]. Philadelphia: Lippincott Williams & Wilkins, 2001: 1204.
30. Yarchoan R, Little RF. Immunosuppression-related malignancies. In:DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and practice of oncology[J]. Philadelphia: Lippincott Williams & Wilkins, 2001:2575.
31. Rosenberg S. Principles of cancer management: Biologic therapy. In: DeVita VT, Hellman S, Rosenberg SA, ed. Cancer: Principles and practicesof oncology[J]. Philadelphia: Lippincott Williams & Wilkins, 2001:307.
32. Diehl V, Hauch P, Harris N. Hodgkin's Disease. In: DeVita VT, Hellman S, Rosenberg SA, ed. Cancer: Principles and practice of oncology[J]. Philadelphia: Lippincott Williams & Wilkins, 2001: 2339.
33. Alamartine E, Sabido O, Berthoux F. In-vitro effects of Cyclosporin A,FK506, 6-mercaptopurine, and prednisolone on lymphokine-activated killer cells[J]. Nephrol Dial Transplant 1994; 9: 1456.
34. Tamura F, Masuhara A, Sakaida I, et al. FK506 promotes liver regeneration by suppressing natural killer cell activity[J]. J Gastroenterol Hepatol 1998; 13: 703.
35. Fung JJ, Jain A, Kwak EJ, et al. De novo malignancies after liver transplantation: a major cause of late death[J]. Liver Transpl 2001; 7 (Suppl):S109.
36. Engels EA, Goedert JJ. Human immunodeficiency virus/acquired immunodeficiency syndrome and cancer: past, present, and future[J]. J Natl Cancer Inst 2005; 97: 407.
37. Muller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology[J]. Ann Hematol2005;84: 1.
38. Moore PS, Gao SJ, Dominguez G, et al. Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae[J]. J Virol 1996; 70: 549.
39. Penn I. Kaposi's sarcoma in transplant recipients [J]. Transplantation 1997; 64: 669.
40. Woodle ES, Hanaway M, Buell J, et al. Kaposi sarcoma: an analysis of the US and international experiences from the Israel Penn International Transplant Tumor Registry[J]. Transplant Proc 2001; 33: 3660.
41. Meyer T, Arndt R, Nindl I, et al. Association of human papillomavirus infections with cutaneous tumors in immunosuppressed patients[J]. Transpl Int 2003; 16: 146.
42. Euvrard S, Chardonnet Y, Pouteil-Noble C, et al. Association of skin malignancies with various and multiple carcinogenic and noncarcinogenic human papillomaviruses in renal transplant recipients [J]. Cancer 1993; 72: 2198.
43. Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation[J]. Transplantation 2004; 77: 1777.
44. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism[J]. Nature 1999; 397: 530.
45. Shihab FS, Bennett WM, Isaac J, et al. Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephro toxicity [J]. Kidney Int 2003; 63: 522.
46. Reichenspurner H. Overview of tacrolimus-based immunosuppression after heart or lung transplantation[J]. J Heart Lung Transplant 2005; 24: 119.
47. Herman M, Weinstein T, Korzets A, et al. Effect of Cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients [J]. J Lab Clin Med 2001; 137: 14.
48. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism[J]. Nature 1999; 397: 530.
49. Shihab FS, Bennett WM, Isaac J, et al. Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity[J]. Kidney Int 2003; 63: 522.
50. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression[J]. Transplantation 2003; 76: 597.
51. Sakai M, Miyake H, Tashiro S, et al. Inhibitory effect of FK506 and cyclosporine A on the growth and invasion of human liver cancer cells[J]. J Med Invest 2004; 51: 63.
52. Dharnidharka VR, Ho PL, Stablein DM, et al. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study[J]. Pediatr Transplant 2002; 6: 396.
53. Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation[J]. Transplantation 2004; 77: 1777.
54. Dharnidharka VR, Ho PL, Stablein DM, et al. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study [J]. Pediatr Transplant 2002; 6: 396.
55. Taylor L, Hughes RA, McPherson K. The risk of cancer from azathioprine as a treatment for multiple sclerosis [J]. Eur J Neurol 2004; 11: 141.
56. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States[J]. Am J Transplant 2004; 4: 905.
57. Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine[J]. Science 1996; 273: 1109.
58. Offman J, Opelz G, Doehler B, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation[J]. Blood 2004; 104: 822.
59. Tressler RJ, Garvin LJ, Slate DL. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo[J]. Int J Cancer 1994; 57:568.
60. Weber G, Hager JC, Lui MS, et al. Biochemical programs of slowly and rapidly growing human colon carcinoma xenografts. Cancer Res 1981; 41: 854. 58. Natsumeda Y, Prajda N, Donohue JP, et al. Enzymic capacities of purine de novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues [J]. Cancer Res 1984; 44: 2475.
61. Nagai M, Natsumeda Y, Konno Y, et al. Selective up-regulation of type II inosine 5=-monophosphate dehydrogenase messenger RNA expression in human leukemias[J]. Cancer Res 1991; 51: 3886.
62. Weber G, Hager JC, Lui MS, et al. Biochemical programs of slowly and rapidly growing human colon carcinoma xenografts [J]. Cancer Res 1981; 41: 854.
63. Jackson RC, Weber G, Morris HP. IMP dehydrogenase, an enzyme linked with proliferation and malignancy [J]. Nature 1975; 256: 331.
64. Yu J, Lemas V, Page T, et al. Induction of erythroid differentiation in K562 cells by inhibitors of inosine monophosphate dehydrogenase [J]. Cancer Res 1989; 49: 5555.
65. Ohsugi Y, Suzuki S, Takagaki Y. Antitumor and immunosuppressive effects of mycophenolic acid derivatives [J]. Cancer Res 1976; 36: 2923.
66. Carter SB, Franklin TJ, Jones DF, et al. Mycophenolic acid: an anticancer compound with unusual properties[J]. Nature 1969; 223: 848.
67. Engl T, Makarevic J, Relja B, et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy [J]. BMC Cancer 2005; 5: 4.
68. Wang K, Zhang H, Li Y, et al. Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review[J]. Transplant Proc 2004; 36: 2068.
69. Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis[J]. Kidney Int 2003; 63: 917.
70. Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas[J]. Cancer Res 2003; 63: 4472.
71. Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas[J]. Cancer Res 2003; 63: 4472.
72. Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas[J]. Cancer Res 2003; 63: 4472.
73. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor[J]. Nat Med 2002; 8: 128.
74. Buck E, Eyzaguirre A, Brown E, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors[J]. Mol Cancer Ther. 2006 Nov;5(11):2676-84.
75. Trotter JF. Sirolimus in liver transplantation[J]. Transplant Proc 2003; 35:193S
76. Yakupoglu Y, Knight R, Katz S. Low incidence of malignancy among sirolimus-cyclosporine treated transplant recipients[J]. Am J Transplant 2004; 3 (Suppl 5): 187.
77. Kahan B, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience [J]. Transplant Proc 2003; 35: 25S.
78. Swinnen LJ, Fisher RI. OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause of lymphoproliferative disorders associated with transplantation [J]. Curr Opin Nephrol Hypertens 1993; 2: 670.
79. Lenner R, Padilla ML, Teirstein AS, et al. Pulmonary complications in cardiac transplant recipients [J]. Chest 2001; 120: 508.
80. Cherikh WS, KauffmanHM,McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation [J]. Transplantation 2003; 76: 1289.
81. Ruiz P, Soares MF, Garcia M, et al. Lymphoplasmacytic hyperplasia(possibly pre-PTLD) has varied expression and appearance in intestinal transplant recipients receiving Campath immunosuppression[J]. Transplant Proc 2004; 36: 386.
82. Kovarik JM, Schmouder RL, Slade AJ. Overview of FTY720 clinical pharmacokinetics and pharmacology. Ther Drug Monit 2004; 26: 585.
83. Ueda H, Takahara S, Itoh S, et al. Preoperative administration of FTY720 prolonged renal allograft survival[J]. Transpl Immunol 2005; 14:453
84. Naparstek E. The role of the anti-CD20 antibody rituximab in hematopoietic stem cell transplantation for non-Hodgkin's lymphoma[J]. CurrHematol Rep 2005; 4: 276.
85. Shroff R, Rees L. The post-transplant lymphoproliferative disorder-a literature review[J]. Pediatr Nephrol 2004; 19: 369.
86. Cao S, Cox K, Esquivel CO, et al. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation[J]. Transplantation 1998; 66: 851.
87. Dotti G, Fiocchi R, Motta T, et al. Epstein-Barr virus-negative lymphoproliferative disorders in long-term survivors after heart, kidney, and liver transplant[J]. Transplantation 2000; 69: 827.
88. Aull MJ, Buell JF, Trofe J, et al. Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry[J]. Transplantation 2004; 78: 1676.
89. Merchen T, Gupta M, First MR, et al. PTLD following lung transplantation [Abstract]. Am J Transplant 2003; 3: 157.
90. Hanaway MJ, Buell JF, Woodle ES, et al. Effect of sites of presentation of PTLD markedly influences survival after solid organ transplantation [J]. Am J Transplant 2004; 8: 521.
91. Castellano-Sanchez AA, Li S, Qian J, et al. Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol 2004; 121: 246.
92. Hanaway M, Buell J, Woodle E, et al. Effect of PTLD-sites of presentation on survival after liver transplantation[J]. Liver Transpl 2003; 9: C33.
93. Buell JF, Gross TG, Hanaway MJ, et al. Post transplant lymphoproliferative disorder: the significance of central nervous system involvement [Abstract]. Am J Transplant 2002; 2: 373.
94. Gross T. Low-dose chemotherapy for children with post-transplant lymphoproliferative disease[J]. Recent Results Cancer Res 2002; 159: 96.
95. Pescovitz M, Funch D, Schneider G, Walker A. Antiviral use and its association with post-transplant lymphoproliferative disorder (PTLD) in renal transplant patients[J]. Am J Transplant 2003; 3: 447.
96. Humar A, Hebert D, Davies D, et al. A multi-center randomized trial of ganciclovir vs. ganciclovir plus immune globulin for prophylaxis against EBV related PTLD in high risk solid organ transplant recipients: one-year results [Abstract]. Am J Transplant 2003; 3: 446.
97. Niitsu N, Hayama M, Okamoto M, et al. Phase I study of rituximab- CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma[J]. Clin Cancer Res 2004; 10: 4077.
98. Mellstedt H. Monoclonal antibodies in human cancer[J]. Drugs Today (Barc) 2003; 39 (Suppl C): 1.
99. Ganne V, Siddiqi N, Kamaplath B, et al. Humanized anti-CD20 monoclonal antibody (rituximab) treatment for post-transplant lymphoproliferative disorder [J]. Clin Transplant 2003; 17: 417.
100. Jain A. Single center experience with rituximab for the treatment of PTLD in transplant recipients [J]. Am J Transplant 2003; 3: 446.
101. Orjuela M, Gross TG, Cheung YK, et al. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation[J]. Clin Cancer Res 2003; 9 (Suppl): 3945S.
102. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation[J]. N Engl J Med 2003; 348: 1681.
103. Dreno B, Mansat E, Legoux B, Litoux P. Skin cancers in transplant patients[J]. Nephrol Dial Transplant 1998; 13: 1374.
104. Gupta AK, Cardella CJ, Haberman HF. Cutaneous malignant neoplasms in patients with renal transplants [J]. Arch Dermatol 1986; 122: 1288.
105. Penn I, Brunson ME. Cancers after cyclosporine therapy. Transplant Proc 1988; 20:885.) [J]
106. Ulrich C, Schmook T, Sachse MM, et al. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients [J]. Dermatol Surg 2004; 30: 622.